- Home
- SEE vs PCVX Comparison
SEE vs PCVX Comparison
Compare SEE & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEE
- PCVX
- Stock Information
- Founded
- SEE 1960
- PCVX 2013
- Country
- SEE United States
- PCVX United States
- Employees
- SEE N/A
- PCVX N/A
- Industry
- SEE Major Chemicals
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SEE Industrials
- PCVX Health Care
- Exchange
- SEE Nasdaq
- PCVX Nasdaq
- Market Cap
- SEE 3.8B
- PCVX 4.5B
- IPO Year
- SEE N/A
- PCVX 2020
- Fundamental
- Price
- SEE $30.57
- PCVX $31.16
- Analyst Decision
- SEE Buy
- PCVX Strong Buy
- Analyst Count
- SEE 12
- PCVX 10
- Target Price
- SEE $37.92
- PCVX $136.50
- AVG Volume (30 Days)
- SEE 1.8M
- PCVX 2.2M
- Earning Date
- SEE 05-06-2025
- PCVX 05-07-2025
- Dividend Yield
- SEE 2.61%
- PCVX N/A
- EPS Growth
- SEE N/A
- PCVX N/A
- EPS
- SEE 2.02
- PCVX N/A
- Revenue
- SEE $5,335,500,000.00
- PCVX N/A
- Revenue This Year
- SEE N/A
- PCVX N/A
- Revenue Next Year
- SEE $2.03
- PCVX N/A
- P/E Ratio
- SEE $14.90
- PCVX N/A
- Revenue Growth
- SEE N/A
- PCVX N/A
- 52 Week Low
- SEE $22.78
- PCVX $27.66
- 52 Week High
- SEE $41.14
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SEE 64.71
- PCVX 36.73
- Support Level
- SEE $27.34
- PCVX $28.09
- Resistance Level
- SEE $28.10
- PCVX $33.75
- Average True Range (ATR)
- SEE 0.90
- PCVX 2.54
- MACD
- SEE 0.54
- PCVX 1.12
- Stochastic Oscillator
- SEE 90.87
- PCVX 35.61
About SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food care includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Product care includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.